Cat.No. | Name | Information |
---|---|---|
M1962 | Lenalidomide | Lenalidomide is a thalidomide analog known to display TNF-α secretion inhibition and possesses immunomodulatory properties. |
M6224 | Etanercept | Etanercept is a dimer fusion protein that binds tumor necrosis factor (TNF) as a TNF inhibitor. Etanercept competitively inhibits the binding of TNF-α and TNF-β to TNF receptors on the cell surface, rendering tumor necrosis factor biologically inactive. |
M25324 | Licaminlimab | Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation. |
M25300 | Placulumab | Placulumab (ART621) is an anti-TNF α domain antibody construction. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis. |
M25275 | Lucatumumab | Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research. |
M25270 | Conatumumab | Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. . |
M25264 | Dacetuzumab | Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research. |
M25239 | Iratumumab | Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL). |
M25227 | Golimumab | Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research. |
M25217 | Belimumab | Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. |
M25208 | Teneliximab | Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion. |
M25192 | Inezetamab | Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody. |
M25187 | Toralizumab | Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive drug, has the potential for active systemic lupus erythematosus (SLE) research. |
M25185 | Frexalimab | Frexalimab (SAR441344; INX-021) is a monoclonal antibody targeting the CD40 ligand (CD40L). Frexalimab has the potential for multiple sclerosis research. |
M25049 | Tecaginlimab | Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity. |
M24988 | Ragifilimab | Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research. |
M24986 | Ruplizumab | Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research. |
M24973 | Relfovetmab | Relfovetmab is an anti-NGF monoclonal antibody (mAb). |
M24929 | Tanfanercept | Tanfanercept (HL036337) is an anti-TNF-α monoclonal antibody. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model. |
M24928 | Teclistamab | Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM). |
M24925 | Benufutamab | Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects. |
M24906 | Brentuximab | Brentuximab is a chimeric antibody targeting CD30. Brentuximab can be used for the research of emerging targeted therapies. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.